Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine   Commentaries on Twitter Interesting results in the #PANAMO trial of vilobelimab, an anti-C5a antibody, in critically ill ICU patients w/ COVID19. People on MV (n=386) randomized to […]

The post RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19. appeared first on Links Medicus.